Global Public Health Partnering Directory 2012-2018: Deal Trends, Players and Financials

Dublin, March 20, 2018 -- The "Global Public Health Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Public Health Partnering 2012 to 2018 provides the full collection of Public Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.

The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report scope

Global Public Health Partnering 2012 to 2018 includes:

• Trends in Public Health dealmaking in the biopharma industry since 2012
• Analysis of Public Health deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Public Health deal contract documents
• Comprehensive access to over 3500 Public Health deal records
• The leading Public Health deals by value since 2012
• Most active Public Health dealmakers since 2012
  

Available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Public Health dealmaking

2.1. Introduction
2.2. Public Health partnering over the years
2.3. Public Health partnering by deal type
2.4. Public Health partnering by industry sector
2.5. Public Health partnering by stage of development
2.6. Public Health partnering by technology type
2.7. Public Health partnering by therapeutic indication

Chapter 3 - Financial deal terms for Public Health partnering

3.1. Introduction
3.2. Disclosed financials terms for Public Health partnering
3.3. Public Health partnering headline values
3.4. Public Health deal upfront payments
3.5. Public Health deal milestone payments
3.6. Public Health royalty rates

Chapter 4 - Leading Public Health deals and dealmakers

4.1. Introduction
4.2. Most active in Public Health partnering
4.3. List of most active dealmakers in Public Health
4.4. Top Public Health deals by value

Chapter 5 - Public Health contract document directory

5.1. Introduction
5.2. Public Health partnering deals where contract document available

Chapter 6 - Public Health dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Public Health therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/9k99b7/global_public?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals